Kou Qin

Kou Qin, PhD, serves as the Managing Director of Investment at Eisai Innovation Inc, focusing on strategic investments in aging-related diseases, including neurodegeneration and cancer. Since March 2021, Kou has enhanced partnerships between portfolio companies and collaborating pharmaceutical and venture capital firms. In addition to this role, Kou holds several positions, including Board Observer at ProTgen Inc. and RiboX Therapeutics, and Investor roles at eGenesis, Iambic Therapeutics, Tune Therapeutics, and Pyrotech Therapeutics. Educational background includes a PhD in Pharmacology and Neuroscience from the Medical College of Georgia at Augusta University, a Master of Science in Biostatistics and Bioinformatics from Harvard University, and a Bachelor's degree in Biomedical Engineering from Huazhong University of Science and Technology.